Golan T, et al. - In patients with metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy, researchers sought to appraise the effectiveness of olaparib as maintenance therapy in patients who also have a germline BRCA1 or BRCA2 mutation via a randomized, double-blind, placebo-controlled, phase 3 trial. They randomized 154 patients in a 3:2 ratio to receive maintenance olaparib tablets (300 mg twice daily) or placebo. As per outcomes, maintenance using olaparib vs placebo led to longer progression-free survival among patients with a germline BRCA mutation and metastatic pancreatic cancer (7.4 months vs. 3.8 months).